Results 171 to 180 of about 216,066 (333)

Previously Uncharacterised Aliphatic Amino Acid Positions Modulate the Apparent Catalytic Activity of the EAL Domain of ZMO_1055 and Other Cyclic Di-GMP-Specific EAL Phosphodiesterases. [PDF]

Microb Biotechnol
Cao LY, Zhang X, Bai FW, Römling U.
europepmc   +1 more source

Notes on Three Palustrine Natural Community Types in the Arkansas Ozarks [PDF]

, 1985
Orzell, Steve L., Pell, William F., Tucker, Gary E.   +2 more
core   +2 more sources

Differential segment‐specific signalling pathways for guanylate cyclase C‐activated anion secretion in murine ileocolon

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Guanylate cyclase‐C (GC‐C) is the receptor for endogenous (uro)guanylin peptides, bacterial toxins and pharmacological analogues. Receptor activation leads to intestinal fluid loss, but also activates an antiproliferative pathway and is a promising target in colorectal cancer therapy.
Renjie Xiu, Johannes Reiner, Franz Hofmann, Azam Salari, Ursula Seidler   +4 more
wiley   +1 more source

Anti-Inflammatory and Anti-apoptotic Effects of Phosphodiesterase Inhibitors Against Streptozocin-induced Diabetic Nephropathy. [PDF]

In Vivo
Mehanna OM, Elesawy BH, Elaskary A, Hassan MGM, Ahmed WMS, El Monsef ASA, Abbas MAM, Hammad AM, Elgazzar UB, Gabr NM, El-Sharnouby M, Sharahili AI, Khalifa MM.   +12 more
europepmc   +1 more source

Evaluation of pyrrolidine and pyrazolone derivatives as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1).

Tetrahedron Letters, 2015
E. Amata, N. Bland, R. Campbell, M. Pollastri   +3 more
semanticscholar   +1 more source

A role for epithelium‐derived 6‐nitrodopamine on human ureter contractility

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose To investigate the basal release of 6‐nitrodopamine (6‐ND) from human isolated ureter and the role of this novel catecholamine in the ureter contractility. Experimental Approach Ureters from 67 brain‐dead organ donors (40 males and 27 females) were used during kidney transplantation procedures.
Wilmar Azal Neto, Denis Lima Oliveira, José Britto‐Júnior, Alex Henrique Miller, Flaviano Lorenzon, Felipe Fernandes Jacintho, Valéria Barbosa de Souza, Fernanda Viviane Mariano, André Almeida Schenka, Fabiola Zakia Mónica, Adriano Fregonesi, Edson Antunes, Gilberto De Nucci   +12 more
wiley   +1 more source

An Update on Phosphodiesterase Mutations Underlying Genetic Etiology of Hearing Loss and Retinitis Pigmentosa

Frontiers in Genetics, 2018
Rahul Mittal, Nicole Bencie, James M. Parrish, George Liu, Jeenu Mittal, Denise Yan, Xue Zhong Liu, Xue Zhong Liu   +7 more
doaj   +1 more source

Phosphodiesterase inhibitors for the management of lower urinary tract symptoms in men without benign prostatic hyperplasia: a systematic review. [PDF]

Transl Androl Urol
Bakhsh A, Rajih E, Barayan GA, Garah E, Khan I, Alrehaili Z, Alhejaili S, Almuways M, Aloufi T, Alnazawi H, Alharbi A, Farghal D, Badawi A.   +12 more
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Exploring Patient Pathways and Care Situations in Men With Erectile Dysfunction in Different PDE-5 Inhibitor Regulatory Settings. [PDF]

Int J Public Health
May U, Werthner Q, Weigmann H, Bauer C.
europepmc   +1 more source